About
Surfix develops a photonic diagnostics platform for point-of-care testing, comprising a photonic biosensor with proprietary nanocoatings, microfluidic cartridges, and a dedicated desktop reader. The company targets high-sensitivity, lab-level precision detection for applications such as disease diagnosis, monitoring, antibiotic susceptibility testing, and drug development.
Explore Surfix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.